PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5% analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals >or=65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99% confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80% in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50% in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P < 0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P < 0.05). A more than 20% greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION: Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.
PURPOSE: To determine whether comorbidities are more prevalent among individuals with neovascular age-related macular degeneration (NV-AMD) than individuals without AMD. METHODS: This 2-year, retrospective, case-control study included Medicare beneficiaries (standard 5% analytic sample) continuously enrolled from January 1, 2003, to December 31, 2004, excluding those in managed care plans. The NV-AMD cohort included individuals >or=65 at baseline with a diagnosis of NV-AMD in 2003 and 2004. Age-, gender-, and race-matched controls were selected from those with no AMD. Comparisons were made for 13 general categories of non-eye-related diseases and 18 specific comorbidities based on ICD-9-CM codes. Two-year prevalence was calculated by condition and cohort; odds ratios and 99% confidence intervals were calculated (logistic regression). RESULTS: Analyses included 26,057 subjects and an equal number of controls. Nearly all subjects had at least one comorbidity, and >80% in each cohort had five or more comorbidities across general disease categories. Prevalence of 7/13 general disease categories exceeded 50% in both cohorts; rates for 12/13 categories were significantly higher in those with NV-AMD (P < 0.001). Prevalence of 13/14 non-eye-related and 4/4 eye-related specific comorbidities was significantly higher among NV-AMD subjects (P < 0.05). A more than 20% greater odds for NV-AMD subjects was noted for hypertension, hypercholesterolemia, emphysema, chronic obstructive pulmonary disease, atherosclerosis, arthritis, coronary heart disease, cataract, glaucoma, and myopia. CONCLUSION:Patients with NV-AMD are significantly more likely to have comorbidities, many of which could be life-threatening.
Authors: David J Ramsey; James C McCullum; Elise E Steinberger; Yubo Zhang; Amer Mosa Alwreikat; Michael L Cooper; Shiyoung Roh; Paul R Cotran Journal: Eye (Lond) Date: 2021-08-12 Impact factor: 4.456
Authors: Matt Trinh; Natalie Eshow; David Alonso-Caneiro; Michael Kalloniatis; Lisa Nivison-Smith Journal: Invest Ophthalmol Vis Sci Date: 2022-10-03 Impact factor: 4.925
Authors: Joseph Thomas; Sohail Mohammad; Richard Charnigo; Judit Baffi; Ahmed Abdel-Latif; Khaled M Ziada Journal: South Med J Date: 2015-08 Impact factor: 0.954
Authors: Joanna Miłkowska-Dymanowska; Adam J Białas; Anna Zalewska-Janowska; Paweł Górski; Wojciech J Piotrowski Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-07-15
Authors: Christoph Kern; Dun Jack Fu; Karsten Kortuem; Josef Huemer; David Barker; Alison Davis; Konstantinos Balaskas; Pearse A Keane; Tom McKinnon; Dawn A Sim Journal: Br J Ophthalmol Date: 2019-07-18 Impact factor: 4.638